Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.
2026 · 1st Quarter (Jan 1 - Mar 31)
FERRING PHARMACEUTICALS, INC.
Filed by BAKER & HOSTETLER LLP.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 19, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- BAKER & HOSTETLER LLP
- Filing UUID
- 5eb33ffb-c865-4bb8-a79b-999fef2ea400
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.